½ÃÀ庸°í¼­
»óǰÄÚµå
1775653

¾Èµå·Î°Õ Â÷´Ü ¿ä¹ý ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : ADT À¯Çüº°, ÀûÀÀÁõº°, Åõ¿© °æ·Îº°, ȯÀÚ ¼Ó¼ºº°, À¯Åë ä³Îº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2025-2032³â)

Androgen Deprivation Therapy Market Size, Share, and Growth Analysis, By Type of ADT (GnRH Analogues, Anti-androgens), By Indication, By Route of Administration, By Patient Demographics, By Distribution Channel, By Region - Industry Forecast 2025-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: SkyQuest | ÆäÀÌÁö Á¤º¸: ¿µ¹® 189 Pages | ¹è¼Û¾È³» : 3-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¾Èµå·Î°Õ Â÷´Ü ¿ä¹ý ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 67¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â 70¾ï 8,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â 109¾ï 4,000¸¸ ´Þ·¯·Î ¼ºÀåÇϸç, ¿¹Ãø ±â°£(2025-2032³â)ÀÇ CAGRÀº 5.6%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è ¾Èµå·Î°Õ Â÷´Ü ¿ä¹ý ½ÃÀåÀº Àü¸³¼±¾Ï ¹ßº´·ü Áõ°¡¿Í È£¸£¸ó ¹Î°¨¼º Á¾¾ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¾à¹°Àü´ÞÀÇ Çõ½Å, ƯÈ÷ Àå½Ã°£ ÀÛ¿ëÇÏ´Â ÁÖ»çÁ¦ ¹× °æ±¸¿ë ¾à¹°·Î ÀÎÇØ Ä¡·á ¿É¼ÇÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °í·ÉÈ­ »çȸ¿¡¼­ÀÇ Áø´ÜÀ² Çâ»ó, À¯¸®ÇÑ »óȯ Á¤Ã¥, µðÁöÅÐ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ »ç¿ëÀ¸·Î ÀÌ·¯ÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ È¯ÀÚÀÇ Á¢±Ù¼ºÀÌ ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ °³¹ßµµ»ó±¹¿¡¼­´Â ÀáÀçÀûÀÎ ½ÉÀå ºÎÀÛ¿ë°ú ³ôÀº ºñ¿ë µîÀÇ ¹®Á¦°¡ ¿©ÀüÈ÷ Å« À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÇâÈÄ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ÃÖÀûÈ­µÈ Ä¡·á¸¦ À§ÇÑ AIÀÇ ÅëÇÕ, ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ºÎ»ó, ½Ç½Ã°£ È£¸£¸ó ¾ïÁ¦ ¸ð´ÏÅ͸µÀÇ ¹ßÀü µîÀÌ ÀÖÀ¸¸ç, ÀÌ ¸ðµç °ÍÀÌ Àå±âÀûÀÎ ÀÓ»óÀû È¿°ú¿Í ½ÃÀå »ó¿ëÈ­¸¦ Çü¼ºÇÒ ¼ö Àִ ż¼¸¦ °®Ãß°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

¼­·Ð

  • Á¶»çÀÇ ¸ñÀû
  • Á¶»ç ¹üÀ§
  • Á¤ÀÇ

Á¶»ç ¹æ¹ý

  • Á¤º¸ Á¶´Þ
  • 2Â÷¿Í 1Â÷ µ¥ÀÌÅÍ ¹æ¹ý
  • ½ÃÀå ±Ô¸ð ¿¹Ãø
  • ½ÃÀåÀÇ ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ

°³¿ä

  • ¼¼°è ½ÃÀå Àü¸Á
  • °ø±Þ°ú ¼ö¿ä µ¿Ç⠺м®
  • ºÎ¹®º° ±âȸ ºÐ¼®

½ÃÀå ¿ªÇаú Àü¸Á

  • ½ÃÀå °³¿ä
  • ½ÃÀå ±Ô¸ð
  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀΰú ±âȸ
    • ¾ïÁ¦¿äÀΰú °úÁ¦
  • PorterÀÇ »ê¾÷ ºÐ¼®

ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®

  • ÁÖ¿ä ¼º°ø ¿äÀÎ
  • °æÀïÀÇ Á¤µµ
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ½ÃÀå ¿¡ÄڽýºÅÛ
  • ½ÃÀåÀÇ ¸Å·Â Áö¼ö(2024³â)
  • PESTEL ºÐ¼®
  • °Å½Ã°æÁ¦ ÁöÇ¥
  • ¹ë·ùüÀÎ ºÐ¼®
  • °¡°Ý ºÐ¼®
  • »ç·Ê ¿¬±¸
  • °í°´ ±¸¸Å Çൿ ºÐ¼®

¾Èµå·Î°Õ Â÷´Ü ¿ä¹ý ½ÃÀå ±Ô¸ð : ADT À¯Çüº° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • GnRH ¾Æ³¯·Î±×
  • Ç׾ȵå·Î°Õ

¾Èµå·Î°Õ Â÷´Ü ¿ä¹ý ½ÃÀå ±Ô¸ð : ÀûÀÀÁõº° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • ±¹¼Ò¼º Àü¸³¼±¾Ï
  • ÁøÇ༺ Àü¸³¼±¾Ï

¾Èµå·Î°Õ Â÷´Ü ¿ä¹ý ½ÃÀå ±Ô¸ð : Åõ¿© °æ·Îº° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • ±ÙÀ°ÁÖ»ç
  • ÇÇÇÏ ÁÖ»ç

¾Èµå·Î°Õ Â÷´Ü ¿ä¹ý ½ÃÀå ±Ô¸ð : ȯÀÚ ¼Ó¼ºº° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • 40-60¼¼ ³²¼º
  • 61-75¼¼ ³²¼º
  • 75¼¼ ÀÌ»ó ³²¼º

¾Èµå·Î°Õ Â÷´Ü ¿ä¹ý ½ÃÀå ±Ô¸ð : À¯Åë ä³Îº° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • º´¿ø
  • Àü¹® ¾ÏŬ¸®´Ð
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹

¾Èµå·Î°Õ Â÷´Ü ¿ä¹ý ½ÃÀå ±Ô¸ð : Áö¿ªº° & CAGR(2025-2032)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´ Áö¿ª
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä« Áö¿ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • GCC ±¹°¡
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

°æÀï Á¤º¸

  • »óÀ§ 5»çÀÇ ºñ±³
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2024³â)
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤ÅÃÇÑ Àü·«
  • ÃÖ±Ù ½ÃÀå µ¿Çâ
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
  • ÁÖ¿ä ±â¾÷ÀÇ ±â¾÷ °³¿ä
    • ±â¾÷ÀÇ »ó¼¼
    • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
    • ±â¾÷ÀÇ ºÎ¹®º° Á¡À¯À² ºÐ¼®
    • ¸ÅÃâÀÇ Àü³â´ëºñ ºñ±³(2022-2024³â)

ÁÖ¿ä ±â¾÷ °³¿ä

  • Ferring B V
  • AstraZeneca
  • Bayer AG
  • Astellas Pharma Inc
  • Johnson & Johnson
  • Foresee Pharmaceuticals Co Ltd
  • Viatris
  • Verity Pharmaceuticals Inc
  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • Tolmar Pharmaceuticals Inc

°á·Ð°ú Á¦¾È

KSA 25.07.31

Global Androgen Deprivation Therapy Market size was valued at USD 6.7 billion in 2023 and is poised to grow from USD 7.08 billion in 2024 to USD 10.94 billion by 2032, growing at a CAGR of 5.6% during the forecast period (2025-2032).

The Global Androgen Deprivation Therapy market is experiencing growth driven by the increasing incidence of prostate cancer and heightened awareness of hormone-sensitive tumors. Innovations in drug delivery, particularly long-acting injectables and oral medications, are enhancing treatment options. Improved diagnosis rates among aging populations, favorable reimbursement policies, and the use of digital monitoring systems are further expanding patient access to these therapies. Nevertheless, challenges such as potential cardiac side effects and high costs in developing countries pose significant barriers. Key future trends include the integration of AI for optimized therapies, the rise of biosimilars, and advancements in real-time hormone suppression monitoring, all of which are poised to shape long-term clinical efficacy and market commercialization.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Androgen Deprivation Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Androgen Deprivation Therapy Market Segments Analysis

Global Androgen Deprivation Therapy Market is segmented by Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel and region. Based on Type of ADT, the market is segmented into GnRH Analogues and Anti-androgens. Based on Indication, the market is segmented into Localized Prostate Cancer and Advanced Prostate Cancer. Based on Route of Administration, the market is segmented into Intramuscular and Subcutaneous. Based on Patient Demographics, the market is segmented into Men aged 40-60, Men aged 61-75 and Men above 75. Based on Distribution Channel, the market is segmented into Hospitals, Specialized Cancer Clinics, Online Pharmacies and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Androgen Deprivation Therapy Market

The increasing global prevalence of prostate cancer among older men is significantly driving the demand for androgen deprivation therapy. This treatment remains the preferred approach for managing hormone-sensitive prostate cancer, particularly in cases of advanced or metastatic disease. Additionally, initiatives aimed at enhancing screening programs and raising awareness around early detection contribute to the growing volumes of patients seeking this therapy. As more individuals recognize the importance of timely diagnosis and intervention, the market for androgen deprivation therapy is poised for continued growth in response to these escalating needs within the healthcare landscape.

Restraints in the Global Androgen Deprivation Therapy Market

The Global Androgen Deprivation Therapy market faces significant restraints due to the high costs associated with innovative treatments, including new oral blockers and long-acting injectables. These expenses often exceed the capabilities of standard insurance and public health budgets, particularly in developing nations. This creates a major barrier to affordability, compounded by inadequate reimbursement for patients and a lack of coordination within healthcare systems. As a result, many individuals in these regions may struggle to access necessary therapies, limiting the overall growth and potential of the market. Addressing these financial and systemic challenges is essential for improving patient access to effective treatments.

Market Trends of the Global Androgen Deprivation Therapy Market

The Global Androgen Deprivation Therapy (ADT) market is witnessing a significant shift toward new-generation oral hormone blockers, driven by patient preference for convenience and reduced clinic visits. By early 2024, oral luteinizing hormone-releasing hormone (LHRH) antagonists and antiandrogens have become first-line outpatient treatment options for prostate cancer, aligning with a broader trend toward decentralized care. This transition from injectable therapies to oral administration not only enhances patient compliance but also transforms treatment paradigms, indicating a robust growth trajectory for the ADT market. As healthcare systems adapt to these innovations, the demand for oral therapies is poised to accelerate.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies
  • Customer Buying Behavior Analysis

Global Androgen Deprivation Therapy Market Size by Type of ADT & CAGR (2025-2032)

  • Market Overview
  • GnRH Analogues
  • Anti-androgens

Global Androgen Deprivation Therapy Market Size by Indication & CAGR (2025-2032)

  • Market Overview
  • Localized Prostate Cancer
  • Advanced Prostate Cancer

Global Androgen Deprivation Therapy Market Size by Route of Administration & CAGR (2025-2032)

  • Market Overview
  • Intramuscular
  • Subcutaneous

Global Androgen Deprivation Therapy Market Size by Patient Demographics & CAGR (2025-2032)

  • Market Overview
  • Men aged 40-60
  • Men aged 61-75
  • Men above 75

Global Androgen Deprivation Therapy Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Specialized Cancer Clinics
  • Online Pharmacies
  • Retail Pharmacies

Global Androgen Deprivation Therapy Market Size & CAGR (2025-2032)

  • North America (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • US
    • Canada
  • Europe (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Type of ADT, Indication, Route of Administration, Patient Demographics, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Ferring B V
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Foresee Pharmaceuticals Co Ltd
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Viatris
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Verity Pharmaceuticals Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Tolmar Pharmaceuticals Inc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦